Table 5. Adverse events occurred during treatment and hospitalization.
| Parameters | DEB-TACE group (N=171) | cTACE group (N=164) | P value |
|---|---|---|---|
| During treatment | |||
| Pain (n/%) | 33 (19.3) | 18 (11.0) | 0.034 |
| Pain grade (NRS) (n/%) | 0.040 | ||
| Mild pain | 23 (69.7) | 17 (94.4) | |
| Moderate pain | 8 (24.2) | 1 (5.6) | |
| Severe pain | 2 (6.1) | 0 (0.0) | |
| Nausea/vomiting (n/%) | 14 (8.2) | 12 (7.3) | 0.766 |
| Rise in blood pressure (n/%) | 4 (2.3) | 1 (0.6) | 0.192 |
| During hospitalization | |||
| Pain (n/%) | 40 (23.4) | 29 (17.7) | 0.196 |
| Pain grade (NRS) (n/%) | 0.449 | ||
| Mild pain | 33 (82.5) | 26 (89.7) | |
| Moderate pain | 7 (17.5) | 2 (6.9) | |
| Severe pain | 0 (0.0) | 1 (3.4) | |
| Fever (n/%) | 31 (18.1) | 15 (9.1) | 0.017 |
| Nausea/vomiting (n/%) | 17 (9.9) | 12 (7.3) | 0.393 |
Data were presented as count (%). Comparison between 2 groups was determined by Chi-square test or Wilcoxon rank sum test. P value <0.05 was considered significant, and the significant results were shown in boldface. DEB-TACE, drug-eluting bead transarterial chemoembolization; cTACE, conventional transarterial chemo-embolization; NRS, numeric rating scale.